Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06864403 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 4 to 5v6
  2. Start date: Jun 12, 2025 to Aug 12, 2025v5
  3. Study sites revised (4)v4 See this version in full on ClinicalTrials.gov ↗
  4. Study sites: 2 to 4v3
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 2 · Start date changed from estimate of Apr 2025 to Jun 12, 2025v2 Show 2 more changesShow less
    • Study sites: 1 to 2
    • Start date changed from estimate of Apr 2025 to Jun 12, 2025
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn if mirikizumab works to treat pouch disorders in adults. The main questions it aims to answer are: Does mirikizumab reduce symptoms of pouch disorders Participants will: Take mirikizumab every 4 weeks for one year Visit the clinic once every month for two months and at the end of the study Keep a diary of their symptoms
Trial Details
NCT Number NCT06864403
Lead Sponsor University of North Carolina, Chapel Hill
Collaborators: Eli Lilly and Company
Conditions Pouchitis, Pouches, Ileoanal, Pouch, Ileal
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov